Download Free Sample Report

Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinsons Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
This report contains market size and forecasts of Neurological Disorder Drugs in global, including the following market information:

• Global Neurological Disorder Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Neurological Disorder Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Neurological Disorder Drugs companies in 2021 (%)

The global Neurological Disorder Drugs market was valued at 19820 million in 2021 and is projected to reach US$ 25180 million by 2028, at a CAGR of 3.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Antipsychotic Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neurological Disorder Drugs include Novartis, GlaxoSmithKline, Merck & Co., Bayer, AstraZeneca, Boehringer Ingelheim and Teva Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neurological Disorder Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neurological Disorder Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neurological Disorder Drugs Market Segment Percentages, by Type, 2021 (%)

• Antipsychotic
• Hypnotic & Sedative
• Analgesics
• Anticoagulants
• Others

Global Neurological Disorder Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neurological Disorder Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic

Global Neurological Disorder Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neurological Disorder Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Neurological Disorder Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Neurological Disorder Drugs revenues share in global market, 2021 (%)
• Key companies Neurological Disorder Drugs sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Neurological Disorder Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novartis
• GlaxoSmithKline
• Merck & Co.
• Bayer
• AstraZeneca
• Boehringer Ingelheim
• Teva Pharmaceutical